Advertisement

Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [18F]fluciclovine PET/CT

  • Akinyemi A. AkintayoEmail author
  • O. A. Abiodun-Ojo
  • C. Weber
  • J. Sharma
  • C. Cohen
  • G. Sica
  • R. Halkar
  • M. M. Goodman
  • D. M. Schuster
Brief Article
  • 14 Downloads

Abstract

Purpose

To evaluate the ability of anti-1-amino-3-anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid ([18F]fluciclovine) positron emission tomography/X-ray computed tomography (PET/CT) in comparison to Technetium-99m 2-methoxy isobutyl isonitrile ([99mTc]sestamibi) single-photon emission computed tomography/CT (SPECT/CT) for the localization of hyperfunctioning parathyroid glands in patients with hyperparathyroidism.

Procedures

Four patients with hyperparathyroidism underwent 60-minutes sequential neck and thorax PET/CT after [18F]fluciclovine (352 ± 28 MBq) injection. Lesion uptake and target-to-background ratios (TBR) were compared with [99mTc]sestamibi (798 ± 27 MBq) SPECT/CT in the same patient.

Results

Both techniques detected 4/5 hyperfunctioning parathyroid glands identified at surgery. The highest [18F]fluciclovine uptake and TBRs were at 5–9 min with rapid washout. [99mTc]sestamibi had significantly higher TBRs compared with [18F]fluciclovine (5–9 min) for blood pool (10.9 ± 4.7 vs 1.3 ± 0.6; p < 0.01) and reference muscle backgrounds (5.8 ± 3.0 vs 1.7 ± 0.6; p < 0.01), with non-significant trend for thyroid tissue background (1.3 ± 0.5 vs 1.1 ± 0.5; p = 0.73).

Conclusion

Hyperfunctioning parathyroid glands can be detected on [18F]fluciclovine PET/CT at early imaging, but conspicuity (TBR) is better with [99mTc]sestamibi. [18F]fluciclovine PET/CT does not seem promising in the detection of hyperfunctioning parathyroid glands.

Key words

Hyperfunctioning parathyroid gland [18F]fluciclovine PET/CT SPECT/CT [99mTc]sestamibi 

Notes

Acknowledgements

We gratefully acknowledge the contributions of Ronald Crowe, RPh, BCNP and the cyclotron/synthesis team from Emory University Center for Systems Imaging.

Compliance with Ethical Standards

This feasibility pilot study was approved by the institutional review board and was performed in compliance with Health Insurance Portability and Accountability Act (HIPPA).

Conflicts of Interest

Emory University and Dr. Mark Goodman are eligible to receive royalties for [18F]fluciclovine. Blue Earth Diagnostics Ltd. provided [18F]fluciclovine synthesis cassettes to Emory University for this project. Although not impacting this study, funding is or has been received from Blue Earth Diagnostics Ltd. and Nihon Medi-Physics Co. Ltd. through the Emory University Office of Sponsored Projects for other clinical trials using FACBC ([18F]fluciclovine).

References

  1. 1.
    Bilezikian JP, Bandeira L, Khan A, Cusano NE (2018) Hyperparathyroidism. Lancet 391:168–178CrossRefGoogle Scholar
  2. 2.
    Udelsman R, Lin Z, Donovan P (2011) The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 253:585–591CrossRefGoogle Scholar
  3. 3.
    Kunstman JW, Kirsch JD, Mahajan A, Udelsman R (2013) Clinical review: parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 98:902–912CrossRefGoogle Scholar
  4. 4.
    Kluijfhout WP, Pasternak JD, Beninato T, Drake FT, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Hope TA, Suh I (2017) Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. Eur J Radiol 88:117–128CrossRefGoogle Scholar
  5. 5.
    Lopez Hanninen E, Vogl TJ et al (2000) Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Investig Radiol 35:426–430CrossRefGoogle Scholar
  6. 6.
    Gotway MB, Reddy GP, Webb WR, Morita ET, Clark OH, Higgins CB (2001) Comparison between MR imaging and 18Tc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 218:783–790CrossRefGoogle Scholar
  7. 7.
    Stern S, Tzelnick S, Mizrachi A, Cohen M, Shpitzer T, Bachar G (2018) Accuracy of neck ultrasonography in predicting the size and location of parathyroid adenomas. Otolaryngol Head Neck Surg 159:968–972.  https://doi.org/10.1177/0194599818792236 CrossRefGoogle Scholar
  8. 8.
    Mitchell BK, Merrell RC, Kinder BK (1995) Localization studies in patients with hyperparathyroidism. Surg Clin North Am 75:483–498CrossRefGoogle Scholar
  9. 9.
    Ruda JM, Hollenbeak CS, Stack BC Jr (2005) A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 132:359–372CrossRefGoogle Scholar
  10. 10.
    Biertho LD, Kim C, Wu HS, Unger P, Inabnet WB (2004) Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism. J Am Coll Surg 199:229–233CrossRefGoogle Scholar
  11. 11.
    Chien D, Jacene H (2010) Imaging of parathyroid glands. Otolaryngol Clin N Am 43:399–415CrossRefGoogle Scholar
  12. 12.
    Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y (2014) Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin Nucl Med 39:1033–1038CrossRefGoogle Scholar
  13. 13.
    Parvinian A, Martin-Macintosh EL, Goenka AH, Durski JM, Mullan BP, Kemp BJ, Johnson GB (2018) 11C-choline PET/CT for detection and localization of parathyroid adenomas. AJR Am J Roentgenol 210:418–422CrossRefGoogle Scholar
  14. 14.
    Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, Tsybrovskyy O, Langsteger W, Pirich C (2018) 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 45:1762–1771CrossRefGoogle Scholar
  15. 15.
    Quak E, Blanchard D, Houdu B, le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard JM, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N (2018) F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 45:658–666CrossRefGoogle Scholar
  16. 16.
    Weber T, Gottstein M, Schwenzer S, Beer A, Luster M (2017) Is C-11 methionine PET/CT able to localise sestamibi-negative parathyroid adenomas? World J Surg 41:980–985CrossRefGoogle Scholar
  17. 17.
    Oksuz MO, Dittmann H, Wicke C et al (2011) Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol 17:297–307Google Scholar
  18. 18.
    Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Pampaloni MH, Suh I (2016) Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck's Arch Surg 401:925–935CrossRefGoogle Scholar
  19. 19.
    Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339CrossRefGoogle Scholar
  20. 20.
    Neumann DR, Esselstyn CB Jr, MacIntyre WJ et al (1994) Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. Radiology 192:509–512CrossRefGoogle Scholar
  21. 21.
    Sisson JC, Thompson NW, Ackerman RJ, Wahl RL (1994) Use of 2-[F-18]-fluoro-2-deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology 192:280CrossRefGoogle Scholar
  22. 22.
    Lange-Nolde A, Zajic T, Slawik M, Brink I, Reincke M, Moser E, Hoegerle S (2006) PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. Nuklearmedizin 45:193–196CrossRefGoogle Scholar
  23. 23.
    Hayakawa N, Nakamoto Y, Kurihara K, Yasoda A, Kanamoto N, Miura M, Inagaki N, Togashi K (2015) A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl Med Commun 36:53–59CrossRefGoogle Scholar
  24. 24.
    Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L (2018) Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging.  https://doi.org/10.1007/s00259-018-4123-z

Copyright information

© World Molecular Imaging Society 2019

Authors and Affiliations

  1. 1.Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular ImagingEmory University HospitalAtlantaUSA
  2. 2.Department of SurgeryEmory UniversityAtlantaUSA
  3. 3.Department of Pathology and Laboratory MedicineEmory UniversityAtlantaUSA

Personalised recommendations